{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:47:24Z","timestamp":1790873244174,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      In recent years, phenobarbital, as an antiepileptic drug, has become less popular based on adverse events, especially cognitive and behavioural side effects. Despite the development of better tolerated new generation AEDs, phenobarbital is still widely used particularly in developing countries because of its low cost. The purpose of this review was to:\n                      <jats:italic>(i)<\/jats:italic>\n                      investigate whether phenobarbital can be safely used as an antiepileptic drug and\n                      <jats:italic>(ii)<\/jats:italic>\n                      determine the questions which need to be addressed in order to comprehensively and adequately evaluate the safety of phenobarbital for the treatment of epilepsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The literature was searched using the Cochrane Central Register of randomised controlled trials (1800\u20102009), Medline (1966\u20102009), Embase (1966\u20102009) and three Chinese databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty studies were finally included in this systematic review. The determination of adverse effects of combined antiepileptic drugs (AEDs) from different studies was complicated by numerous factors including study design, different descriptions of adverse events and a lack of standardised data collection. These factors may also have been responsible for the heterogeneity present in the meta\u2010analysis. The data did not demonstrate any evidence of association between phenobarbital and a higher risk of adverse events. However, phenobarbital appeared to be associated with a higher rate of adverse drug reaction related withdrawal (ADR\u2010related withdraw), compared to carbamazepine, valproic acid and phenytoin. This may have been due to a concern for possible adverse effects of phenobarbital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Phenobarbital was associated with a higher rate of drug withdrawal although there was no evidence to suggest that phenobarbital caused more adverse events compared to carbamazepine, valproic acid or phenytoin. However, in the case of pregnant women, it is important for clinicians to evaluate the benefits and risks of phenobarbital administration before making a final recommendation. Furthermore, unified scales for the assessment of cognitive function should be applied for future studies particularly in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1684\/epd.2011.0444","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T09:24:19Z","timestamp":1564737859000},"page":"349-365","source":"Crossref","is-referenced-by-count":47,"title":["Side effects of phenobarbital in epilepsy: a systematic review"],"prefix":"10.1002","volume":"13","author":[{"given":"Ling\u2010Li","family":"Zhang","sequence":"first","affiliation":[{"name":"Chinese Cochrane Centre and Chinese Evidence\u2010Based Medicine Centre West China Hospital Sichuan University West China Medical School P.R. China"},{"name":"Department of Pharmacy West China Second University Hospital P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Nan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy West China Second University Hospital P.R. China"},{"name":"West China School of Pharmacy Sichuan University Chengdu 610041 P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You\u2010Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Cochrane Centre and Chinese Evidence\u2010Based Medicine Centre West China Hospital Sichuan University West China Medical School P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"274","volume-title":"Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions","author":"Aronson JK","year":"2006"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39022.436389.BE"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-006-0539-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00851.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00516.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90074-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91176-U"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.44"},{"key":"e_1_2_8_10_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1","author":"Higgins JPT","year":"2009"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441504"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.6.13.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00084-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.12704.x"},{"key":"e_1_2_8_15_1","first-page":"133","article-title":"In utero exposure to antiepileptic drugs: teratogenicity and neonatal morbidity","volume":"7","author":"Lateef TM","year":"2007","journal-title":"Pediatric Neurol"},{"key":"e_1_2_8_16_1","first-page":"94","article-title":"Antiepileptic drugs and teratogenesis in two consective cohorts: Changes in prescription policy perelleled by changes in pattern of malformations","volume":"42","author":"Lindhout D","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.3_Part_1.391"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb03623.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01693.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","unstructured":"NaghmeA SmithT VintenC et al.Common antiepileptic drugs in pregnancy in women with epilepsy.Cochrane Database of Systematic Rev2004; Issue 3. Art. No: CD004848. DOI:10.1002\/14651858.CD004848.","DOI":"10.1002\/14651858.CD004848"},{"key":"e_1_2_8_22_1","first-page":"532","article-title":"Treatment with phenobarbital and monitoring of epileptic patients in rural Mali","volume":"80","author":"Nimaga K","year":"2002","journal-title":"Bull World Health Organ"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06250-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01480.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1179\/027249302125001598"},{"key":"e_1_2_8_26_1","first-page":"89","article-title":"Epilepsy, pregnancy, and major birth anomalies","volume":"42","author":"Tanganelli P","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","unstructured":"TaylorS Tudur SmithC WilliamsonPR et al.Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic\u2010clonic seizures Cochrane Database Syst Rev2003; Issue 2. Art. No: CD002217.DOI:10.1002\/14651858.CD00217.","DOI":"10.1002\/14651858.CD002217"},{"key":"e_1_2_8_28_1","first-page":"549","article-title":"Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double\u2010blind study","volume":"3","author":"Thilothammal N","year":"1996","journal-title":"Indian Pediatr"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.08.015"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","unstructured":"Tudur SmithC MarsonAG WilliamsonPR. Carbamazepine versus phenobarbitone monotherapy for epilepsy.Cochrane Database of Syst Rev2003; Issue 1. Art. No: CD001904. DOI:10.1002\/14651858CD001904","DOI":"10.1002\/14651858.CD001904"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)90640-D"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.80.2.165"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70254-4"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540150044014"},{"key":"e_1_2_8_35_1","unstructured":"WellsGA SheaB O'ConnellD et al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses. Ottawa health research institution.2008;http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm."},{"key":"e_1_2_8_36_1","volume-title":"Initiative of support to people with epilepsy","author":"WHO.","year":"1990"},{"key":"e_1_2_8_37_1","volume-title":"Epilepsy in the WHO Africa region, bridging the gap: the global campaign against epilepsy \u201cout of the shadows.\u201d","author":"WHO.","year":"2004"},{"key":"e_1_2_8_38_1","unstructured":"WHO.Fact sheet N\u00b0999. January2009;http:\/\/www.who.int\/mediacentre\/factsheets\/fs999\/en\/index.html."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.12.003"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2011.0444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:22:25Z","timestamp":1710764545000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2011.0444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1684\/epd.2011.0444"],"URL":"https:\/\/doi.org\/10.1684\/epd.2011.0444","archive":["Portico"],"relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s00228-016-2168-0","asserted-by":"object"}]},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}